Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.

  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2016. CA Cancer J Clin2016;66:730.

  • 2.

    Cancer Stat Facts: Myeloma. National Cancer Institute Surveillane, Epidemiology, and End Results Program Web site. Avilable at http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed January 24 2017.

    • Search Google Scholar
    • Export Citation
  • 3.

    BrennerHGondosAPulteD. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood2008;111:25212526.

    • Search Google Scholar
    • Export Citation
  • 4.

    KumarSKRajkumarSVDispenzieriA. Improved survival in multiple myeloma and the impact of novel therapies. Blood2008;111:25162520.

  • 5.

    PalumboAAndersonK. Multiple myeloma. N Engl J Med2011;364:10461060.

  • 6.

    AndersonKC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res2011;17:12251233.

  • 7.

    HideshimaTAndersonK. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer2002;2:927937.

  • 8.

    DispenzieriAKyleRMerliniG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia2009;23:215224.

    • Search Google Scholar
    • Export Citation
  • 9.

    KuhnemundALiebischPBauchmullerK. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol2009;135:477484.

    • Search Google Scholar
    • Export Citation
  • 10.

    DurieBGHarousseauJLMiguelJS. International uniform response criteria for multiple myeloma. Leukemia2006;20:14671473.

  • 11.

    KyleRAGertzMAWitzigTE. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003;78:2133.

  • 12.

    XiongWWuXStarnesS. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood2008;112:42354246.

    • Search Google Scholar
    • Export Citation
  • 13.

    DrachJAckermannJFritzE. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood1998;92:802809.

    • Search Google Scholar
    • Export Citation
  • 14.

    Avet-LoiseauHAttalMMoreauP. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood2007;109:34893495.

    • Search Google Scholar
    • Export Citation
  • 15.

    GertzMALacyMQDispenzieriA. Clinical implications of t(11;14) (q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood2005;106:28372840.

    • Search Google Scholar
    • Export Citation
  • 16.

    GutierrezNCCastellanosMVMartinML. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia2007;21:143150.

    • Search Google Scholar
    • Export Citation
  • 17.

    RossFMAvet-LoiseauHAmeyeG. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica2012;97:12721277.

    • Search Google Scholar
    • Export Citation
  • 18.

    HanamuraIStewartJPHuangY. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood2006;108:17241732.

    • Search Google Scholar
    • Export Citation
  • 19.

    CarrascoDRTononGHuangY. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell2006;9:313325.

    • Search Google Scholar
    • Export Citation
  • 20.

    RosinolLCarrioABladeJ. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol2005;130:729732.

    • Search Google Scholar
    • Export Citation
  • 21.

    DispenzieriARajkumarSVGertzMA. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc2007;82:323341.

    • Search Google Scholar
    • Export Citation
  • 22.

    KumarSKMikhaelJRBuadiFK. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc2009;84:10951110.

    • Search Google Scholar
    • Export Citation
  • 23.

    MoreauPAttalMGarbanF. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia2007;21:20202024.

    • Search Google Scholar
    • Export Citation
  • 24.

    FonsecaRBergsagelPLDrachJ. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia2009;23:22102221.

    • Search Google Scholar
    • Export Citation
  • 25.

    ZhouYBarlogieBShaughnessyJDJr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia2009;23:19411956.

    • Search Google Scholar
    • Export Citation
  • 26.

    DecauxOLodeLMagrangeasF. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol2008;26:47984805.

    • Search Google Scholar
    • Export Citation
  • 27.

    ShaughnessyJDJrZhanFBuringtonBE. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood2007;109:22762284.

    • Search Google Scholar
    • Export Citation
  • 28.

    KuiperRBroylAde KnegtY. A gene expression signature for high-risk multiple myeloma. Leukemia2012;26:24062413.

  • 29.

    MoulopoulosLADimopoulosMAWeberD. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol1993;11:13111315.

    • Search Google Scholar
    • Export Citation
  • 30.

    ZamagniECavoM. The role of imaging techniques in the management of multiple myeloma. Br J Haematol2012;159:499513.

  • 31.

    DurieBWaxmanAD'AgnoloAWilliamsCM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med2002;43:14571463.

  • 32.

    SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361366.

    • Search Google Scholar
    • Export Citation
  • 33.

    ZamagniEPatriarcaFNanniC. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with upfront autologous transplantation. Blood2011;118:59895995.

    • Search Google Scholar
    • Export Citation
  • 34.

    NanniCZamagniECelliM. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med2013;38:e7479.

    • Search Google Scholar
    • Export Citation
  • 35.

    GreippPRLustJAO'FallonWM. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993;81:33823387.

    • Search Google Scholar
    • Export Citation
  • 36.

    RajkumarSVDimopoulosMAPalumboA. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol2014;15:e538548.

    • Search Google Scholar
    • Export Citation
  • 37.

    GreippPRSan MiguelJDurieBGM. International Staging System for multiple myeloma. J Clin Oncol2005;23:34123420.

  • 38.

    PalumboAAvet-LoiseauHOlivaS. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol2015;33:28632869.

    • Search Google Scholar
    • Export Citation
  • 39.

    BladeJSamsonDReeceD. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol1998;102:11151123.

    • Search Google Scholar
    • Export Citation
  • 40.

    RajkumarSV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol2011;86:5765.

  • 41.

    PalumboARajkumarSVSan MiguelJF. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol2014;32:587600.

    • Search Google Scholar
    • Export Citation
  • 42.

    KumarSPaivaBAndersonKC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol2016;17:e328346.

    • Search Google Scholar
    • Export Citation
  • 43.

    Avet-LoiseauHLeleuXRousselM. Bortezomib plus dexamethasone induction improves outcome of patients With t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol2010;28:46304634.

    • Search Google Scholar
    • Export Citation
  • 44.

    MateosMV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev2010;36(Suppl 2):S2432.

  • 45.

    SiegelDMartinTNookaA. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica2013;98:17531761.

    • Search Google Scholar
    • Export Citation
  • 46.

    Chanan-KhanASonneveldPSchusterM. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 47.

    MateosMHernandezJHernandezM. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood2006;108:21652172.

    • Search Google Scholar
    • Export Citation
  • 48.

    RichardsonPSonneveldPSchusterM. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med2005;352:24872498.

  • 49.

    Kyprolis (carfilzomib) for injection. FDA Web site. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/ucm441458.htm. Accessed January 24 2017.

    • Search Google Scholar
    • Export Citation
  • 50.

    MoreauPPylypenkoHGrosickiS. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol2011;12:431440.

    • Search Google Scholar
    • Export Citation
  • 51.

    ArnulfBPylypenkoHGrosickiS. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica2012;97:19251928.

    • Search Google Scholar
    • Export Citation
  • 52.

    RichardsonPGWellerELonialS. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood2010;116:679686.

    • Search Google Scholar
    • Export Citation
  • 53.

    KumarSFlinnIRichardsonPG. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood2012;119:43754382.

    • Search Google Scholar
    • Export Citation
  • 54.

    RousselMLauwers-CancesVRobillardN. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol2014;32:27122717.

    • Search Google Scholar
    • Export Citation
  • 55.

    DurieBHoeringARajkumarSV. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777 [abtract]. Blood2015;126:Abstract 25.

    • Search Google Scholar
    • Export Citation
  • 56.

    ReederCBReeceDEKukretiV. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia2009;23:13371341.

    • Search Google Scholar
    • Export Citation
  • 57.

    EinseleHLiebischPLangerC. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) [abstract]. Blood2009;114:Abstract 131.

    • Search Google Scholar
    • Export Citation
  • 58.

    ReederCBReeceDEKukretiV. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol2014;167:563565.

    • Search Google Scholar
    • Export Citation
  • 59.

    ReederCBReeceDEKukretiV. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood2010;115:34163417.

    • Search Google Scholar
    • Export Citation
  • 60.

    SonneveldPSchmidt-WolfIGvan der HoltB. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol2012;30:29462955.

    • Search Google Scholar
    • Export Citation
  • 61.

    HarousseauJLAttalMAvet-LoiseauH. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol2010;28:46214629.

    • Search Google Scholar
    • Export Citation
  • 62.

    RichardsonPGBarlogieBBerensonJ. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med2003;348:26092617.

  • 63.

    MoreauPAvet-LoiseauHFaconT. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood2011;118:57525758; quiz 5982.

    • Search Google Scholar
    • Export Citation
  • 64.

    ZonderJACrowleyJHusseinMA. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232 [abstract]. Blood2007;110:Abstract 77.

    • Search Google Scholar
    • Export Citation
  • 65.

    RajkumarSVJacobusSCallanderN. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2007;110:Abstract 74.

    • Search Google Scholar
    • Export Citation
  • 66.

    RajkumarSVJacobusSCallanderNS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol2010;11:2937.

    • Search Google Scholar
    • Export Citation
  • 67.

    ZangariMTricotGPolavaramL. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol2010;28:132135.

    • Search Google Scholar
    • Export Citation
  • 68.

    PalumboARajkumarSVDimopoulosMA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 69.

    KumarSDispenzieriALacyMQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:20352042.

    • Search Google Scholar
    • Export Citation
  • 70.

    ParipatiHStewartAKCabouS. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:12821284.

    • Search Google Scholar
    • Export Citation
  • 71.

    KumarSGiraltSStadtmauerEA. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood2009;114:17291735.

    • Search Google Scholar
    • Export Citation
  • 72.

    MarkTSternJFurstJR. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant2008;14:795798.

    • Search Google Scholar
    • Export Citation
  • 73.

    NademaneeAPDiPersioJFMaziarzRT. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant2012;18:15641572.

    • Search Google Scholar
    • Export Citation
  • 74.

    DuarteRFShawBEMarinP. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant2011;46:5258.

    • Search Google Scholar
    • Export Citation
  • 75.

    CavoMTacchettiPPatriarcaF. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet2010;376:20752085.

    • Search Google Scholar
    • Export Citation
  • 76.

    KaufmanJLNookaAVranaM. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer2010;116:31433151.

    • Search Google Scholar
    • Export Citation
  • 77.

    RosinolLOriolATeruelAI. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood2012;120:15891596.

    • Search Google Scholar
    • Export Citation
  • 78.

    MoreauPHulinCMACROM. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013-04 trial. Blood2015;126:393393.

    • Search Google Scholar
    • Export Citation
  • 79.

    Arastu-KapurSAnderlJLKrausM. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res2011;17:27342743.

    • Search Google Scholar
    • Export Citation
  • 80.

    KirkCJJiangJMuchamuelT. The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration [abstract]. Blood2008;112:Abstract 2765.

    • Search Google Scholar
    • Export Citation
  • 81.

    SiegelDSMartinTWangM. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood2012;120:28172825.

    • Search Google Scholar
    • Export Citation
  • 82.

    VijRWangMKaufmanJL. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood2012;119:56615670.

    • Search Google Scholar
    • Export Citation
  • 83.

    VijRWangMOrlowskiR. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM) [abstract]. Blood2008;112:Abstract 865.

    • Search Google Scholar
    • Export Citation
  • 84.

    JakubowiakAJDytfeldDGriffithKA. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood2012;120:18011809.

    • Search Google Scholar
    • Export Citation
  • 85.

    KordeNZingoneAKwokM. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed Multiple Myeloma (MM) patients [abstract]. Blood2012;120:Abstract 732.

    • Search Google Scholar
    • Export Citation
  • 86.

    KordeNZingoneAKwokM. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients [abstract]. Blood2013;122:Abstract 538.

    • Search Google Scholar
    • Export Citation
  • 87.

    KumarSKBerdejaJGNiesvizkyR. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol2014;15:15031512.

    • Search Google Scholar
    • Export Citation
  • 88.

    DytfeldDJasielecJGriffithKA. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica2014;99:e162164.

    • Search Google Scholar
    • Export Citation
  • 89.

    ZepedaJ H. VDugganP. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients [abstract]. Blood2014;124:Abstract 5751.

    • Search Google Scholar
    • Export Citation
  • 90.

    RichardsonPWellerELonialS. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood2010;116:679686.

    • Search Google Scholar
    • Export Citation
  • 91.

    RajkumarSVJacobusSCallanderN. A randomized phase III trial of lenalidomide pus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern Cooperative Oncology Group [abstract]. Blood2006;108:Abstract 799.

    • Search Google Scholar
    • Export Citation
  • 92.

    BenboubkerLDimopoulosMADispenzieriA. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med2014;371:906917.

    • Search Google Scholar
    • Export Citation
  • 93.

    AttalMLauwers-CancesVMaritG. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med2012;366:17821791.

    • Search Google Scholar
    • Export Citation
  • 94.

    McCarthyPLOwzarKHofmeisterCC. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med2012;366:17701781.

  • 95.

    UsmaniSSextonRHoeringA. Second malignancies in total therapy 3 trials for newly diagnosed multiple myeloma: influence of lenalidomide versus thalidomide in maintenance phases [abstract]. Blood2011;118:Abstract 823.

    • Search Google Scholar
    • Export Citation
  • 96.

    PalumboABringhenSKumarSK. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol2014;15:333342.

    • Search Google Scholar
    • Export Citation
  • 97.

    DimopoulosMACheungMCRousselM. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica2016;101:363370.

    • Search Google Scholar
    • Export Citation
  • 98.

    NiesvizkyRFlinnIWRifkinR. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract]. Blood2011;118:Abstract 478.

    • Search Google Scholar
    • Export Citation
  • 99.

    KordeNRoschewskiMZingoneA. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol2015;1:746754.

    • Search Google Scholar
    • Export Citation
  • 100.

    SrikanthMDaviesFEWuP. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol2008;81:432436.

    • Search Google Scholar
    • Export Citation
  • 101.

    BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:25742579.

    • Search Google Scholar
    • Export Citation
  • 102.

    KrogerNSayerHGSchwerdtfegerR. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood2002;100:39193924.

    • Search Google Scholar
    • Export Citation
  • 103.

    MoreauPFaconTAttalM. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002;99:731735.

    • Search Google Scholar
    • Export Citation
  • 104.

    SomloGSpielbergerRFrankelP. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res2011;17:174182.

    • Search Google Scholar
    • Export Citation
  • 105.

    AttalMHarousseauJLStoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:9197.

    • Search Google Scholar
    • Export Citation
  • 106.

    ChildJMorganGDaviesF. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:18751883.

    • Search Google Scholar
    • Export Citation
  • 107.

    BarlogieBKyleRAndersonK. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929936.

    • Search Google Scholar
    • Export Citation
  • 108.

    FermandJKatsahianSDivineM. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:92279233.

    • Search Google Scholar
    • Export Citation
  • 109.

    CavoMTacchettiPPatriarcaF. Superior complete response rate and progression-free survival after autologous transplantation with upfront velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 158.

    • Search Google Scholar
    • Export Citation
  • 110.

    FermandJPRavaudPChevretS. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood1998;92:31313136.

    • Search Google Scholar
    • Export Citation
  • 111.

    PalumboACavalloFGayF. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med2014;371:895905.

  • 112.

    PalumboACavalloFGayF. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med2014;371:895905.

  • 113.

    CavoMTacchettiPPatriarcaF. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD [abstract]. Blood2009;114:Abstract 351.

    • Search Google Scholar
    • Export Citation
  • 114.

    HahnTWingardJAndersonK. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant2003;9:437.

    • Search Google Scholar
    • Export Citation
  • 115.

    KumarSLacyMQDispenzieriA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant2004;34:161167.

    • Search Google Scholar
    • Export Citation
  • 116.

    AttalMHarousseauJFaconT. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med2003;349:24952502.

    • Search Google Scholar
    • Export Citation
  • 117.

    StadtmauerEA. Multiple myeloma, 2004—one or two transplants?N Engl J Med2003;349:25512553.

  • 118.

    CavoMTosiPZamagniE. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol2007;25:24342441.

    • Search Google Scholar
    • Export Citation
  • 119.

    SonneveldPvan der HoltBSegerenC. Intensive versus double intensive therapy in untreated multiple myeloma: Updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood2004;104:Abstract 948.

    • Search Google Scholar
    • Export Citation
  • 120.

    GoldschmidtH. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica2005;90(s1):Abstract 38.

    • Search Google Scholar
    • Export Citation
  • 121.

    BarlogieBAttalMCrowleyJ. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol2010;28:12091214.

    • Search Google Scholar
    • Export Citation
  • 122.

    CookGLiakopoulouEPearceR. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant2011;17:16381645.

    • Search Google Scholar
    • Export Citation
  • 123.

    OlinRLVoglDTPorterDL. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant2009;43:417422.

    • Search Google Scholar
    • Export Citation
  • 124.

    BurzynskiJAToroJJPatelRC. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma2009;50:14421447.

    • Search Google Scholar
    • Export Citation
  • 125.

    AlvaresCLDaviesFEHortonC. The role of second autografts in the management of myeloma at first relapse. Haematologica2006;91:141142.

  • 126.

    FenkRLieseVNeubauerF. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma2011;52:14551462.

    • Search Google Scholar
    • Export Citation
  • 127.

    CookGWilliamsCBrownJM. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol2014;15:874885.

    • Search Google Scholar
    • Export Citation
  • 128.

    StadtmauerAPasquiniMBlackwellB. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autohct with len maintenance (TAM) and autohct with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA trial) [abstract]. Blood2016;128:Absrtact LBA-1.

    • Search Google Scholar
    • Export Citation
  • 129.

    CavoMPetrucciMTDi RaimondoF. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup multicenter phase III study of the European Myeloma Network (EMN02/HO95 MM trial). Presented at the 58th Annual Meeting & Exposition; December3–62016; San Diego, California.

    • Search Google Scholar
    • Export Citation
  • 130.

    AunerHWSzydloRRoneA. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after upfront autologous transplantation. Leuk Lymphoma2013;54:22002204.

    • Search Google Scholar
    • Export Citation
  • 131.

    Jimenez-ZepedaVHMikhaelJWinterA. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: Impact on progression-free and overall survival. Biol Blood Marrow Transplant2012;18:773779.

    • Search Google Scholar
    • Export Citation
  • 132.

    SellnerLHeissCBennerA. Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients. Cancer2013;119:24382446.

    • Search Google Scholar
    • Export Citation
  • 133.

    ShahNAhmedFBashirQ. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer2012;118:35493555.

    • Search Google Scholar
    • Export Citation
  • 134.

    KyleRA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol1999;26:7483.

  • 135.

    KumarALoughranTAlsinaM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol2003;4:293304.

    • Search Google Scholar
    • Export Citation
  • 136.

    BrunoBRottaMPatriarcaF. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med2007;356:11101120.

  • 137.

    RosinolLPerez-SimonJASuredaA. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood2008;112:35913593.

    • Search Google Scholar
    • Export Citation
  • 138.

    GarbanFAttalMMichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:34743480.

    • Search Google Scholar
    • Export Citation
  • 139.

    KrishnanAPasquiniMCLoganB. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol2011;12:11951203.

    • Search Google Scholar
    • Export Citation
  • 140.

    BjorkstrandBIacobelliSHegenbartU. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol2011;29:30163022.

    • Search Google Scholar
    • Export Citation
  • 141.

    BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:25742579.

    • Search Google Scholar
    • Export Citation
  • 142.

    MaloneyDMolinaASahebiF. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood2003;102:34473454.

    • Search Google Scholar
    • Export Citation
  • 143.

    CrawleyCLalancetteMSzydloR. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood2005;105:45324539.

    • Search Google Scholar
    • Export Citation
  • 144.

    de LavalladeHEl-CheikhJFaucherC. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant2008;41:953960.

    • Search Google Scholar
    • Export Citation
  • 145.

    PutkonenMKairistoVJuvonenV. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol2010;85:416423.

    • Search Google Scholar
    • Export Citation
  • 146.

    ZeiserRBertzHSpyridonidisA. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant2004;34:923928.

    • Search Google Scholar
    • Export Citation
  • 147.

    van de DonkNWKrogerNHegenbartU. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant2006;37:11351141.

    • Search Google Scholar
    • Export Citation
  • 148.

    LokhorstHMWuKVerdonckLF. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood2004;103:43624364.

    • Search Google Scholar
    • Export Citation
  • 149.

    LokhorstHMSchattenbergACornelissenJJ. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol2000;18:30313037.

    • Search Google Scholar
    • Export Citation
  • 150.

    LokhorstHMSchattenbergACornelissenJJ. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood1997;90:42064211.

    • Search Google Scholar
    • Export Citation
  • 151.

    SalamaMNevillTMarcellusD. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant2000;26:11791184.

  • 152.

    TricotGVesoleDHJagannathS. Graft-versus-myeloma effect: proof of principle. Blood1996;87:11961198.

  • 153.

    AyukFShimoniANaglerA. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia2004;18:659662.

    • Search Google Scholar
    • Export Citation
  • 154.

    PaivaBVidrialesMBCerveroJ. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood2008;112:40174023.

    • Search Google Scholar
    • Export Citation
  • 155.

    RawstronACChildJAde TuteRM. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol2013;31:25402547.

    • Search Google Scholar
    • Export Citation
  • 156.

    KneppersEvan der HoltBKerstenMJ. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood2011;118:24132419.

    • Search Google Scholar
    • Export Citation
  • 157.

    AlsinaMBeckerPSZhongX. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant2014;20:11831189.

    • Search Google Scholar
    • Export Citation
  • 158.

    PalumboAHajekRDelforgeM. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med2012;366:17591769.

  • 159.

    UsmaniSZSextonRHoeringA. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood2012;120:15971600.

    • Search Google Scholar
    • Export Citation
  • 160.

    SinghPPKumarSKLaPlantBR. Lenalidomide maintenance therapy in multiple myeloma: a meta-analysis of randomized trials [asbtract]. Blood2013;22:Abstract 407.

    • Search Google Scholar
    • Export Citation
  • 161.

    MellqvistUHGimsingPHjertnerO. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood2013;121:46474654.

    • Search Google Scholar
    • Export Citation
  • 162.

    NiesvizkyRFlinnIWRifkinRM. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients [abstract]. Blood2010;116:Abstract 619.

    • Search Google Scholar
    • Export Citation
  • 163.

    BerensonJRLichtensteinAPorterL. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol1998;16:593602.

    • Search Google Scholar
    • Export Citation
  • 164.

    BerensonJRLichtensteinAPorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med1996;334:488493.

    • Search Google Scholar
    • Export Citation
  • 165.

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558567.

    • Search Google Scholar
    • Export Citation
  • 166.

    ZervasKVerrouETeleioudisZ. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006;134:620623.

    • Search Google Scholar
    • Export Citation
  • 167.

    MorganGJDaviesFEGregoryWM. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet2010;376:19891999.

    • Search Google Scholar
    • Export Citation
  • 168.

    BoydKMorganGDaviesF. Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results [abstract]. J Clin Oncol2011;29:Abstract 8010.

    • Search Google Scholar
    • Export Citation
  • 169.

    MorganGJDaviesFGregoryW. Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival (OS) benefit associated with treatment with zoledronic acid (ZOL) [abstract]. J Clin Oncol2011;29:Abstract 8083.

    • Search Google Scholar
    • Export Citation
  • 170.

    MorganGJDaviesFEGregoryWM. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res2013;19:60306038.

    • Search Google Scholar
    • Export Citation
  • 171.

    MhaskarRRedzepovicJWheatleyK. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev2012;5:CD003188.

  • 172.

    HuKYahalomJ. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park)2000;14:101108.

  • 173.

    MajorPPColemanRE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol2001;28:1724.

    • Search Google Scholar
    • Export Citation
  • 174.

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558567.

    • Search Google Scholar
    • Export Citation
  • 175.

    PecherstorferMSteinhauerEURizzoliR. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer2003;11:539547.

    • Search Google Scholar
    • Export Citation
  • 176.

    LindsleyHTellerDNoonanB. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med1973;54:682688.

    • Search Google Scholar
    • Export Citation
  • 177.

    LudwigHFritzEKotzmannH. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med1990;322:16931699.

  • 178.

    OsterborgABoogaertsMACiminoR. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood1996;87:26752682.

    • Search Google Scholar
    • Export Citation
  • 179.

    IkhlaqueNSeshadriVKathulaSBaumannM. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol2006;81:420422.

    • Search Google Scholar
    • Export Citation
  • 180.

    BazRLiLKottke-MarchantK. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc2005;80:15681574.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 1427 1427 94
PDF Downloads 491 491 37
EPUB Downloads 0 0 0